GRANOCYTE

*Reduction in the duration of neutropenia following bone-marrow transplantation or peripheral stem cells transplantation for non-myeloid malignancy:* BY SC INJ OR IV INF: Adult: 150 mcg/m2 daily until neutrophil count stable in acceptable range (max. 28 days), to be started the day after transplantation. *Reduction in the duration of neutropenia following treatment with cytotoxic chemotherapy associated with a febrile neutropenia:* BY SC INJ: Adult: 150 mcg/m2 daily until neutrophil countstable in acceptable range (max. 28 days), to be started on the day after completion of chemotherapy. *Mobilization of peripheral blood progenitor cells for harvesting and subsequent INF:* BY SC INJ: Adult: 10 mcg/kg daily for 4-6 days. *Mobilisation of peripheral blood progenitor cells, used following adjunctive myelosuppressive chemotherapy:* BY SC INJ: Adult:150 mcg/m2 daily until neutrophil count stable in acceptable range, to be started 1-5 days after completion of chemotherapy, (for treatment of leucopheresis, consult product literature).

For IV infusion, give intermittently over 30 min in Sodium chloride 0.9%; initially reconstitute with 1ml water for injection provided (do not shake vigorously) then dilute with up to 50ml infusion fluid for each vial of 263 mcg; give over 30 minutes.

Severe congenital neutropenia (Kostmanns syndrome) with abnormal cytogenetics.

Tumours with myeloid characteristics (risk of tumour growth), pre-malignant myeloid conditions; reduced myeloid precursors; monitor leucocyte count (discontinue) treatment if leukocytosis); monitor platelet count and haemoglobin; regular morphological and cytogenetic bone marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukaemia); monitor spleen size; osteoporotic bone disease (monitor bone density if given for more than 6 months); does not prevent other toxic effects of high-dose chemotherapy; pregnancy, breast-feeding.

Mucositis, splenic rupture, toxic epidermal necrolysis, musculoskeletal pain, transient hypoten-sion, disturbances in liver enzymes and serum uric acid; thrombocytopenia; urinary abnormalities including dysuria; allergic reactions (more common after intravenous infusion), proteinuria, haematuria, and transient decrease in blood glucose; on long-term use cutaneous vasculitis, splenic enlargement, hepatomegaly, headache, diarrhoea, anaemia, epistaxis, alopecia, osteoporosis, and rash.